Entera Bio revives estimated $55 million IPO with updated financials
Entera Bio, which is developing oral formulations of treatments for a thyroid condition and osteoporosis, reported financial results for the twelve months ended December 31, 2017, in an amendment filed with the SEC on Thursday.
It originally set terms for a $55 million IPO in January, but postponed the deal a few weeks later. In the updated filing, Entera removed its proposed terms and added warrants to the offering. Maxim Group LLC will now serve as sole bookrunner on the deal.
Entera Bio was founded in 2009 and plans to list on the Nasdaq under the symbol ENTX.
The article Entera Bio revives estimated $55 million IPO with updated financials originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.